Table 1.
Characteristics of patients treated with targeted therapy without CN at MDACC (2003–2009)
| n (%) | |
| Median age (years) at diagnosis (range) | 60.8 (18.2–83.9) |
| Caucasian race | 134 (71.3) |
| Male gender | 123 (65.4) |
| Biopsy site | |
| Kidney | 71 (38.8) |
| Metastasis | 92 (48.9) |
| Kidney and metastasis | 20 (10.6) |
| Not done/unknown | 5 (2.7) |
| Clear cell histologya | 114 (60.6) |
| Renal cell carcinoma (not otherwise specified) | 30 (16.0) |
| Nonclear cell histology | 25 (13.3) |
| Unclassified | 19 (10.1) |
| Sarcomatoid dedifferentiationa | 16 (8.5) |
| Bilateral tumor | 10 (5.3) |
| ECOG PS | |
| 0 | 16 (8.5) |
| 1 | 106 (56.4) |
| 2 | 40 (21.3) |
| 3 | 26 (13.8) |
| Clinical T stage | |
| T1a | 16 (8.5) |
| T1b | 29 (15.4) |
| T2 | 28 (14.9) |
| T3a | 36 (19.2) |
| T3b | 52 (27.7) |
| T3c | 1 (0.5) |
| T4 | 26 (13.8) |
| Number of visceral/bone metastasis | |
| 1 | 68 (36.2) |
| 2 | 73 (38.8) |
| 3 or more | 47 (25.0) |
| Metastatic site | |
| Lung | 128 (68.1) |
| Bone | 83 (44.2) |
| Liver | 58 (30.9) |
| Adrenal | 44 (23.4) |
| Brain | 22 (11.7) |
| Retroperitoneal lymph node | 85 (45.7) |
| Supradiaphragmatic lymph node | 95 (48.7) |
| Other | 26 (13.8) |
| Symptoms at presentation | |
| None | 15 (10.4) |
| Local | 70 (37.2) |
| Metastatic site | 91 (48.4) |
| Constitutional | 77 (41.0) |
| Tumor thrombus | 67 (35.6) |
a
Based on biopsy.
CN, cytoreductive nephrectomy; ECOG, Eastern Cooperative Oncology Group; MDACC, M.D. Anderson Cancer Center; PS, performance status.